CONTEXT: Vascular calcification, an important feature of diabetic vasculopathy, is an active process potentially mediated by endothelial progenitor cells (EPCs) coexpressing the osteoblastic marker osteocalcin (OCN). OBJECTIVE: In this study we tested the hypothesis that cells expressing these markers are associated with the presence of elevated glycated hemoglobin (HbA1c). DESIGN, SETTING, AND PATIENTS: This was a cross-sectional comparison. Patients (n = 133, aged 57.4 ± 15.7 yr) were divided into two groups according to the presence of an HbA1c in a (pre-)diabetic (>5.6) or normal range at the time of blood sampling. METHODS: Using flow cytometry of peripheral blood mononuclear cells (MNCs), cells positive for OCN, the EPC markers (CD34/KDR and CD133(+)/CD34(-)/KDR(+)) and OCN(+) EPCs were counted. RESULTS: Patients with elevated HbA1c compared with those with normal HbA1c had a significantly higher percentage of circulating OCN(+) MNCs [4.6 (interquartile range 2.68-7.81%) vs. 3.12 (0.99-7.81%), P = 0.035], higher numbers of OCN(+)/CD133(+)/CD34(-)/KDR(+) cells [20 (9-74) vs. 8 (0-19) counts per 100,000 gated events, P < 0.001] and a higher fraction of CD133(+)/CD34(-)/KDR(+) and CD34/KDR cells coexpressing OCN (23.7 ± 24.3 vs. 40.5 ± 34.6%, P = 0.002 and 37.1 ± 39.5 vs. 59.7 ± 37.7%, P = 0.002, respectively). The association between circulating OCN(+)/CD133(+)/CD34(-)/KDR(+) cells and an HbA1c in the (pre-) diabetic range remained strong, even after adjusting for differences in obesity and cardiovascular risk factors, disease, and medications in a multivariate model [odds ratio 1.72 (1.21-2.61), P =0.002]. CONCLUSION: This study demonstrated that patients with HbA1c in the (pre-)diabetic range have a significant increase in OCN(+) MNCs, and OCN(+)/CD133(+)/CD34(-)/KDR(+) cells, in particular. Whether these cells increase vascular calcification in (pre-)diabetes warrants further studies.
CONTEXT: Vascular calcification, an important feature of diabetic vasculopathy, is an active process potentially mediated by endothelial progenitor cells (EPCs) coexpressing the osteoblastic marker osteocalcin (OCN). OBJECTIVE: In this study we tested the hypothesis that cells expressing these markers are associated with the presence of elevated glycated hemoglobin (HbA1c). DESIGN, SETTING, AND PATIENTS: This was a cross-sectional comparison. Patients (n = 133, aged 57.4 ± 15.7 yr) were divided into two groups according to the presence of an HbA1c in a (pre-)diabetic (>5.6) or normal range at the time of blood sampling. METHODS: Using flow cytometry of peripheral blood mononuclear cells (MNCs), cells positive for OCN, the EPC markers (CD34/KDR and CD133(+)/CD34(-)/KDR(+)) and OCN(+) EPCs were counted. RESULTS:Patients with elevated HbA1c compared with those with normal HbA1c had a significantly higher percentage of circulating OCN(+) MNCs [4.6 (interquartile range 2.68-7.81%) vs. 3.12 (0.99-7.81%), P = 0.035], higher numbers of OCN(+)/CD133(+)/CD34(-)/KDR(+) cells [20 (9-74) vs. 8 (0-19) counts per 100,000 gated events, P < 0.001] and a higher fraction of CD133(+)/CD34(-)/KDR(+) and CD34/KDR cells coexpressing OCN (23.7 ± 24.3 vs. 40.5 ± 34.6%, P = 0.002 and 37.1 ± 39.5 vs. 59.7 ± 37.7%, P = 0.002, respectively). The association between circulating OCN(+)/CD133(+)/CD34(-)/KDR(+) cells and an HbA1c in the (pre-) diabetic range remained strong, even after adjusting for differences in obesity and cardiovascular risk factors, disease, and medications in a multivariate model [odds ratio 1.72 (1.21-2.61), P =0.002]. CONCLUSION: This study demonstrated that patients with HbA1c in the (pre-)diabetic range have a significant increase in OCN(+) MNCs, and OCN(+)/CD133(+)/CD34(-)/KDR(+) cells, in particular. Whether these cells increase vascular calcification in (pre-)diabetes warrants further studies.
Authors: Cindy Jm Loomans; Rien van Haperen; Jacques M Duijs; Caroline Verseyden; Rini de Crom; Pieter Jm Leenen; Hemmo A Drexhage; Hetty C de Boer; Eelco Jp de Koning; Ton J Rabelink; Frank Jt Staal; Anton Jan van Zonneveld Journal: Mol Med Date: 2009-03-11 Impact factor: 6.354
Authors: Guiti Z Eghbali-Fatourechi; Jesse Lamsam; Daniel Fraser; David Nagel; B Lawrence Riggs; Sundeep Khosla Journal: N Engl J Med Date: 2005-05-12 Impact factor: 91.245
Authors: Carmel M McEniery; Barry J McDonnell; Alvin So; Sri Aitken; Charlotte E Bolton; Margaret Munnery; Stacey S Hickson; Kaisa M Maki-Petaja; John R Cockcroft; Adrian K Dixon; Ian B Wilkinson Journal: Hypertension Date: 2009-01-26 Impact factor: 10.190
Authors: Shripad N Pal; Catherine Rush; Adam Parr; Ann Van Campenhout; Jonathan Golledge Journal: Atherosclerosis Date: 2009-11-10 Impact factor: 5.162
Authors: Mario Gössl; Ulrike I Mödder; Elizabeth J Atkinson; Amir Lerman; Sundeep Khosla Journal: J Am Coll Cardiol Date: 2008-10-14 Impact factor: 24.094
Authors: John T Chow; Sundeep Khosla; L Joseph Melton; Elizabeth J Atkinson; Jon J Camp; Ann E Kearns Journal: J Bone Miner Res Date: 2008-10 Impact factor: 6.741
Authors: Min Wu; Jian-Dong Zhang; Ri-Ning Tang; Steven D Crowley; Hong Liu; Lin-Li Lv; Kun-Ling Ma; Bi-Cheng Liu Journal: Am J Physiol Renal Physiol Date: 2016-08-31
Authors: Julia Collin; Mario Gössl; Yoshiki Matsuo; Rebecca R Cilluffo; Andreas J Flammer; Darrell Loeffler; Ryan J Lennon; Robert D Simari; Daniel B Spoon; Raimund Erbel; Lilach O Lerman; Sundeep Khosla; Amir Lerman Journal: Int J Cardiol Date: 2014-11-26 Impact factor: 4.164
Authors: Francesco Tecilazich; Thanh Dinh; Leena Pradhan-Nabzdyk; Ermelindo Leal; Ana Tellechea; Antonios Kafanas; Charalambos Gnardellis; Mary L Magargee; Andre Dejam; Vasilis Toxavidis; John C Tigges; Eugenia Carvalho; Thomas E Lyons; Aristidis Veves Journal: PLoS One Date: 2013-12-16 Impact factor: 3.240
Authors: Megha Prasad; Martin Reriani; Sundeep Khosla; Mario Gössl; Ryan Lennon; Rajiv Gulati; Abhiram Prasad; Lilach O Lerman; Amir Lerman Journal: Vasc Health Risk Manag Date: 2014-08-26
Authors: Alexei Y Savinov; Maryam Salehi; Manisha C Yadav; Ilian Radichev; José Luis Millán; Olga V Savinova Journal: J Am Heart Assoc Date: 2015-12-16 Impact factor: 5.501